This website is for US healthcare professionals

close-icon

Log In to Bolder Science

or

Don't have an account? Sign Up

close-icon

Please enter your email address.

You will receive a link to create a new password via email.

Log In

close-icon

Create an Account

or
  • 8 characters minimum
  • First character may not be a number
  • Last character may not be a number
close-icon

Welcome and thank you for creating an account!

At Bolder Science, we want your clinical trial search experience to be the best it can be. Complete the following prompts to easily find the trials you are interested in and see trials recruiting near you. You can adjust these selections in your dashboard after creating your account.

Condition Categories

Condition categories are pulled directly from ClinicalTrials.gov. Choose 1 or more condition categories that you are interested in:

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

Set a default location

ELIRA 2: Safety and Effectiveness of TENS Assisted Weight Loss and Appetite Suppression

  • Clinicaltrials.gov identifier

    NCT03936699

  • Recruitment Status

    Completed

  • First Posted

    May 3, 2019

  • Last update posted

    January 8, 2021

Study Description

Brief summary:

The objectives of this study are to demonstrate safety and effectiveness of a wearable patch TENS system (Appendix 2) in driving weight loss and appetite suppression when coupled with an integrated weight loss reduction strategy. The study is designed to demonstrate that TENS stimulation sufficient to drive weight loss and appetite suppression is safe and tolerable when compared to standard of care, and that adverse events/adverse device effects are similar to other TENS device use cases.

  • Condition or Disease:Weight Loss
  • Intervention/Treatment: Device: Transcutaneous Nerve Stimulator (TENS)
    Behavioral: Diet & Exercise
  • Phase: N/A

Detailed Description

Randomized, adaptive parallel arm study. Subjects will be initially screened during a screening period (+/- 7 days). During this screening period, subjects will sign an Informed Consent Form (ICF), have their weight/height and blood pressure measured as part of a physical exam, take a pregnancy test (females of child bearing potential), get blood drawn for analysis (blood lipids, HbA1c), and complete the PHQ-9 and pre-study survey. At the end of the screening period, eligible subjects will be enrolled/randomized in the study and be randomized to either a treatment or control group. After enrolling, both control and treatment subjects will be instructed to follow a healthy diet and reduce calories as desired for the duration of the study and will receive training on the use of the electronic scale and completion of paper diaries. For the treatment group, subjects will be instructed on use of the Elira wearable patch system. Photographs will be taken at the enrollment visit. Following this, subjects will enter the Therapy Period for ~24-weeks. At the 12 week visit, subjects will be assessed for weight loss, blood pressure, blood lipids, HbA1c, patient preference questionnaire and their participation will continue through months 4-6 for the Safety phase of the Therapy Period. The Therapy Period will be considered complete (pending laboratory results, adverse events or serious adverse events). Patient (treatment) photographs will also be taken at the 12 week visit. The study utilizes an adaptive approach where cohorts of enrolled/randomized subjects (in groups of ~25 per arm) are assessed for dose response and progression to achievement of primary and secondary endpoints. Frequent interim endpoint assessment utilizing Markov-chain Monte Carlo (MCMC) methods coupled with Longitudinal analyses will be utilized to determine sample sizes for future cohorts (assessed primarily via Normal dynamic linear modeling [NDLM]). Long term safety of the device will be shown through 6 months of usage.

Study Design

  • Study Type: Interventional
  • Actual Enrollment: 161 participants
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Intervention Model Description: Randomized, adaptive parallel arm study.
  • Masking: None (Open Label) ()
  • Primary Purpose: Treatment
  • Official Title: Safety and Effectiveness of Transcutaneous Electrical Nerve Stimulation (TENS)-Assisted Weight Loss and/or Appetite Suppression
  • Actual Study Start Date: June 2018
  • Actual Primary Completion Date: May 2019
  • Actual Study Completion Date: May 2019

Arms and interventions

Arm Intervention/treatment
Experimental: Treatment
The Transcutaneous Nerve Stimulator (TENS) Elira wearable patch system will be applied to varying locations on the T6/T7 dermatome for 30 minutes three times a day after meals. Subjects will be instructed to follow a 1200 calorie healthy diet and record any changes in appetite.
Device: Transcutaneous Nerve Stimulator (TENS)
The Elira wearable patch system is a Radio Frequency (RF) coupled, wearable transcutaneous electrical nerve stimulator (TENS) device controlled via Bluetooth by a smart phone unit running a custom application which directs therapy from the patch within safe limits set by a clinician and also includes a weight loss diary. Behavioral: Diet & Exercise Subjects to be instructed on a healthy 1200 calorie diet.

Behavioral: Diet & Exercise
Subjects to be instructed on a healthy 1200 calorie diet.
Active Comparator: Control
Open label diet and exercise counseling only. Subjects will be instructed to follow a healthy 1200 calorie diet and record any changes in appetite.
Behavioral: Diet & Exercise
Subjects to be instructed on a healthy 1200 calorie diet.

Outcome Measures

  • Primary Outcome Measures: 1. Change in appetite as measured by a visual analogue scale before and after meals [ Time Frame: 3 months ]
    Appetite Changes [Time Frame: 12 weeks] Percent change in appetite scores at the end of the trial compared to Baseline between Treatment and Control. Subjects are asked to score level of hunger on a Visual Analogue Scale of 1 to 100 before and after meals.
  • 2. Treatment Emergent Adverse Events [ Time Frame: 12 weeks ]
    Treatment Emergent Adverse Events [Time Frame: 12 weeks] Safety/Tolerability will be assessed by the non-inferiority of incidence of serious adverse events (SAEs), unanticipated serious adverse events (USAEs), device-related SAEs (DSAEs), and unanticipated device-related SAEs (UDAEs) that are associated with the TENS therapy throughout the stimulation and the follow-up period versus historical control (compared with other TENS systems).
  • Secondary Outcome Measures: 1. Change in Percent Total Body Weight Loss [ Time Frame: 3 months ]
    Percent reduction in total body weight loss (%TBWL), measured as End Weight - Initial Weight, multiplied by 100, at the end of Experimental period compared to Baseline between Treatment and Control.
  • 2. Changes in BMI [ Time Frame: 3 months ]
    Percent changes in BMI at the end of Experimental period compared to Baseline between Treatment and Control.

Eligibility Criteria

  • Ages Eligible for Study: 18 to 65 Years (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Subject is between 18 - 65 years of age inclusive.

2. Subject has a BMI of 25-35 kg/ m2 inclusive.

3. Subject has signed the informed consent form and is able to comply with study protocol
and adhere to study visit schedule.

4. Subject is able to wear and use a wearable, patch TENS system.

5. Subject is able to use a touch screen hand held smart phone.

6. Subject is fluent in English and can complete questionnaires.

7. Females of childbearing potential (FOCBP) must have a negative urine pregnancy test at
screening or enrollment visit, prior to placement of ELIRA device.

8. Subject is male or non-pregnant, non-lactating female, who agrees to use effective
contraceptive methods throughout the length of the trial based on PI approval.

Exclusion Criteria:

1. Subject has any known gastrointestinal disorder that in the opinion of the PI
precludes enrollment into the trial.

2. Subject has had a prior bariatric procedure or any previous procedure on the stomach.

3. Subject has any significant multisystem disease in the opinion of the PI.

4. Subject has > 6.5 HbA1c.

5. Subject has significant cardiac arrhythmia, ectopy, or significant cardiovascular
disease.

6. Subject has an existing implanted electrical stimulator (e.g., pacemaker, AICD).

7. Subject is a female of child-bearing potential who is pregnant or intends to become
pregnant during the trial period.

8. Subject has current and/or a history of cancer within the past 5 years (not including
basal cell carcinoma or cervical carcinoma in situ).

9. Subject has had a weight change of + 5% of his/her Total Body Weight in the 3 months
prior to screening.

10. Subject has a moderate / severe psychiatric disorder.

11. Subject has a diagnosed neurological disease.

12. Subject has a diagnosed eating disorder.

13. Subject has a skin disorder affecting the thoracic dermatomes.

14. Subject has active or /has ever had shingles in the abdominal area.

15. Subject has abdominal surgery or other scars which may interfere with TENS stimulation
in the opinion of the PI.

16. Subject is currently enrolled in other potentially confounding research.

17. Subject has known allergic reaction to materials in the TENS electrodes and/or is
otherwise unable to tolerate stimulation with the wearable TENS system. This includes
known allergies to latex, nickel and/or hydrogels.

18. Subject has a history of sensitive skin, including eczema wheel-and-flare or other
skin irritation, per PI discretion.

19. Subject is actively participating or unwilling to discontinue participation in another
weight loss program. Subjects may not enroll in paid or unpaid programs that involve
in-person or online apps or coaching, beginning new fitness regimens or utilizing meal
planning or paid nutritional coaching during the course of the ELIRA study

20. Subject is taking weight loss control medications including but not limited to Over
The Counter (OTC) medications, Metformin, and Belviq. (See Appendix 8)

21. Subject is planning any major medical treatments or surgeries that could cause weight
loss.

22. Subject is unable to take anti-nausea medications planned for the study.

23. Inability to walk at least 0.8 kilometers per day (10 minutes of continuous walking).

24. Current smoker or user of nicotine product or smoking cessation within 1 year of the
screening date.

25. History of treatment for or current abuse of drug or alcohol.

26. A score of ≥10 on the Patient Health Questionnaire 9 (PHQ-9), demonstrating moderate
depression.

27. Any subject that the investigator considers inappropriate for the study for medical
reasons.

28. Subject has a history of moderate/severe migraines or other severe headache disorders
requiring the treatment of Topiramate.

29. Subject is on drug therapy which may alter antral motility or appetite, per PI
discretion.

Contacts and Locations

Contacts

Locations

United States, Missouri
West County OB/GYN Specialists
Saint Louis

Sponsors and Collaborators

Elira Therapeutics, Inc.

More Information

  • Responsible Party: Elira Therapeutics, Inc.
  • ClinicalTrials.gov Identifier: NCT03936699 History of Changes
  • Other Study ID Numbers: CD-005
  • First Posted: May 3, 2019 Key Record Dates
  • Last Update Posted: January 8, 2021
  • Last Verified: January 2021
  • Individual Participant
    Data (IPD) Sharing
    Statement:

  • Plan to Share IPD: No
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: Yes
  • Product Manufactured in and Exported from the U.S.: Yes
  • Additional relevant MeSH terms: Body Weight Weight Loss